621 related articles for article (PubMed ID: 17977894)
21. Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis.
Ohki O; Yokozeki H; Katayama I; Umeda T; Azuma M; Okumura K; Nishioka K
Br J Dermatol; 1997 Jun; 136(6):838-45. PubMed ID: 9217814
[TBL] [Abstract][Full Text] [Related]
22. B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation.
Sansom DM; Wilson A; Boshell M; Lewis J; Hall ND
Immunology; 1993 Oct; 80(2):242-7. PubMed ID: 7505258
[TBL] [Abstract][Full Text] [Related]
23. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
[TBL] [Abstract][Full Text] [Related]
24. Involvement of CTLA-4 in T-cell anergy induced by staphylococcal enterotoxin A in vitro.
Xu GL; Zhu XH; Guo B; Wu YZ
Mol Immunol; 2004 May; 41(1):1-8. PubMed ID: 15140570
[TBL] [Abstract][Full Text] [Related]
25. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
26. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
Mukherjee S; Maiti PK; Nandi D
J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
28. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
29. Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86.
Manzotti CN; Liu MK; Burke F; Dussably L; Zheng Y; Sansom DM
Eur J Immunol; 2006 Jun; 36(6):1413-22. PubMed ID: 16708397
[TBL] [Abstract][Full Text] [Related]
30. Requirements for stimulation or anergy induction in alloreactive human T cell clones.
Pawelec G; Kalbacher H; Pohla H; Boshell M; Max H; Friccius H; Adibzadeh M; Hambrecht A; Sansom D
Cell Immunol; 1994 Oct; 158(1):241-52. PubMed ID: 7522128
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal Echinococcus multilocularis infection in C57BL/6 mice affects CD40 and B7 costimulator expression on peritoneal macrophages and impairs peritoneal T cell activation.
Mejri N; Gottstein B
Parasite Immunol; 2006 Aug; 28(8):373-85. PubMed ID: 16879309
[TBL] [Abstract][Full Text] [Related]
32. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
33. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.
Giguère JF; Bounou S; Paquette JS; Madrenas J; Tremblay MJ
J Virol; 2004 Jun; 78(12):6222-32. PubMed ID: 15163715
[TBL] [Abstract][Full Text] [Related]
34. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
[TBL] [Abstract][Full Text] [Related]
35. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
36. Time courses of B7 family molecules expressed on activated T-cells and their biological significance.
Sun ZW; Qiu YH; Shi YJ; Tao R; Chen J; Ge Y; Hu YM; Ma HB; Shi Q; Zhang XG
Cell Immunol; 2005; 236(1-2):146-53. PubMed ID: 16165113
[TBL] [Abstract][Full Text] [Related]
37. Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands.
Lal RB; Rudolph DL; Dezzutti CS; Linsley PS; Prince HE
J Immunol; 1996 Aug; 157(3):1288-96. PubMed ID: 8757637
[TBL] [Abstract][Full Text] [Related]
38. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice.
Asai T; Choi BK; Kwon PM; Kim WY; Kim JD; Vinay DS; Gebhardt BM; Kwon BS
Immunology; 2007 Jul; 121(3):349-58. PubMed ID: 17376197
[TBL] [Abstract][Full Text] [Related]
39. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
Byrne SN; Halliday GM
Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
